Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Next Previous
Trial Profile

A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacritinib (Primary) ; Ruxolitinib
  • Indications Myelofibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PERSIST-2
  • Sponsors Cell Therapeutics; CTI BioPharma

    • Most Recent Events

    • 12 Dec 2023 Results (n=41) evaluating relationship between transfusion independence and reduction in BMF in MF patients treated with pacritinib, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results assessing transfusion response on survival in myelofibrosis patients treated with pacritinib, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results reporting rates of hematologic improvement in PLTs with pacritinib across PERSIST-2 and PAC203 clinical trial, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top